AMAL raised €29M in a Series B round in Nov 2018. The company is based in Geneva, Switzerland. Investors in the round: Boehringer Ingelheim Venture Fund. Data as of 7 Aug 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
This is the company's only recorded round.
